Cardiac Amyloidosis: Diagnosis and Treatment Differ Between ATTR and AL
Background
Diagnosis and treatment of cardiac amyloidosis are advancing based on disease mechanisms. This review in Heart Failure Clinics summarizes advances in imaging diagnosis and various treatment approaches for transthyretin amyloidosis (ATTR), as well as chemotherapy and transplant considerations for immunoglobulin light-chain amyloidosis (AL). It is not a report of a clinical trial newly evaluating the efficacy of a specific treatment.
Cardiac amyloidosis develops when fibrils formed by misfolded proteins deposit in the heart muscle. The review describes transthyretin and immunoglobulin light chains as the main causative proteins and outlines different treatment approaches for each type.
Key findings
Advances in noninvasive imaging have changed the diagnosis of ATTR cardiomyopathy. However, the provided abstract does not specify the conditions under which imaging alone can establish a definitive diagnosis or report the accuracy of individual tests. There is no basis for extending this to mean that imaging alone can diagnose all forms of cardiac amyloidosis.
Treatment approaches introduced for ATTR cardiomyopathy include protein stabilizers, RNA interference, gene editing, and monoclonal antibodies. The abstract does not distinguish individual drugs, specific gene-editing technologies, approval status, or stages of clinical development. The approaches listed therefore cannot all be interpreted as currently available treatments or as therapies used together.
AL cardiomyopathy is primarily associated with plasma cell disorders. The review states that chemotherapy is needed and autologous hematopoietic stem cell transplantation should be considered. Transplantation is not presented as a treatment to be applied uniformly to every patient, and the abstract does not include patient selection criteria.
Implications and outlook
The advances in diagnosis and treatment summarized in the review aim to improve outcomes for patients with cardiac amyloidosis. However, the available abstract provides no patient numbers, comparison groups, follow-up duration, or effect sizes, so it is not possible to determine how much survival or quality of life improves.
The key issue is not only the variety of treatment technologies but also the differences in the disease types each approach targets. Advances in imaging diagnosis and treatment approaches for ATTR should be distinguished from chemotherapy and transplant considerations for AL. The efficacy and conditions of use of individual treatments require further examination of the relevant clinical data.
Source: Heart Failure Clinics review abstract, DOI: 10.1016/j.hfc.2025.11.005.
The diagnosis and treatment of cardiac amyloidosis have undergone rapid evolution over the past decade by harnessing mechanisms of disease pathogenesis. Cardiac amyloidosis is caused by myocardial deposition of fibrils formed by misfolded proteins, namely transthyretin (ATTR) and immunoglobulin light chains (AL). Advances in noninvasive imaging have revolutionized the diagnosis of ATTR cardiomyopathy (CM). Novel treatments for ATTR-CM utilize a range of therapeutic techniques, including protein stabilizers, interfering RNA, gene editing, and monoclonal antibodies. AL-CM, primarily driven by plasma cell dyscrasias, requires treatment with chemotherapy and consideration for autologous stem cell transplant. These significant advances aim to improve patient outcomes in cardiac amyloidosis.
When patients or researchers read about treatment for cardiac amyloidosis, they should first check whether the information concerns ATTR or AL. This review helps distinguish protein stabilizers, RNA interference, gene editing, and monoclonal antibody approaches for ATTR cardiomyopathy from chemotherapy and consideration of autologous hematopoietic stem cell transplantation for AL cardiomyopathy. For example, it provides context to avoid assuming that news about gene editing applies directly to AL treatment as well. The abstract alone, however, cannot guide treatment selection for an individual patient or establish the approval status or clinical benefit of a particular approach.